Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression

Biomarkers in Medicine

Volumn 6, Issue 1, 2012, Pages 119-129

  Wan, Hong I ^a   Soares, Holly ^b   Waring, Jeffrey F ^c  

^a PFIZER INC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c NONE

Author keywords

biomarker; cerebrospinal fluid; monoamines; schizophrenia

Indexed keywords

ALPHA INTERFERON; AMYLOID BETA PROTEIN; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ATOMOXETINE; BIOLOGICAL MARKER; DULOXETINE; GLUCOSE; GLYCINE; HISTAMINE H3 RECEPTOR ANTAGONIST; INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTIC ACID; MUSCARINIC AGENT; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; PF 03654764; PLACEBO; PROTEIN S100B; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; TALSACLIDINE; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; CEREBROSPINAL FLUID EXAMINATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE MARKER; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HEPATITIS C; HUMAN; METABOLOMICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEOMICS; REVIEW; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

ANIMALS; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DEPRESSION; DRUG DISCOVERY; HUMANS; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84856594993     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.98     Document Type: Review

References (79)

1. DiNunzio JC, Williams RO 3rd. CNS disorders - current treatment options and the prospects for advanced therapies. Drug Dev. Ind. Pharm. 34(11), 1141-1167 (2008).
2. Flood DG, Marek GJ, Williams M. Developing predictive CSF biomarkers: a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine. Biochem. Pharmacol. 81(12), 1422-1234 (2011).
3. Feuerstein GZ, Ruffolo RR Jr, Stiles G, Walsh FS, Rutkowski JL. Translational medicine perspectives of biomarkers in drug discovery and development: part 1 target selection and validation - biomarkers take center stage. Am. Drug Discov. 2(5), 36-43 (2007).
4. Feuerstein GZ, Dormer C, Ruffolo RR Jr, Rutkowski JL, Walsh FS, Hurko O. Translational medicine perspectives in drug discovery and development part 2: target compound interaction the vastly neglected biomarkers contributing to early clinical development failure. Am. Drug Discov. 3(2), 48-54 (2008).
5. Feuerstein GZ, Dormer C, Walsh FS, Hurko O, Rutkowski JL. Translational medicine perspectives in drug discovery and development part 3: disease biomarkers, disease modifying biomarkers, disease labeling biomarkers and surrogate biomarkers. Am. Drug Discov. 2(4), 36-41 (2008).
6. Tumani H, Teunissen C, Sussmuth S, Otto M, Ludolph AC, Brettschneider J. Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Exp. Rev. Mol. Diagn. 8(4), 479-494 (2008). (Pubitemid 351962092)
7. Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 8(1), 3 (2011).
8. Peskind E, Nordberg A, Darreh-Shori T, Soininen H. Safety of lumbar puncture procedures in patients with Alzheimer's disease. Curr. Alzheimer Res. 6(3), 290-292 (2009).
9. Arendt K, Demaerschalk BM, Wingerchuk DM, Camann W. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist 15(1), 17-20 (2009).
10. Blennow K, Zetterberg H. Use of CSF biomarkers in Alzheimer's disease clinical trials. J. Nutr. Health Aging 13(4), 358-361 (2009).
11. Lewczuk P, Beck G, Ganslandt O, et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 409(1), 1-4 (2006). (Pubitemid 44740057)
12. Craddock RM, Huang JT, Jackson E, et al. Increased a-defensins as a blood marker for schizophrenia susceptibility. Mol. Cell Proteomics 7(7), 1204-1213 (2008). (Pubitemid 352038267)
13. Mattsson N. CSF biomarkers in neurodegenerative diseases. Clin. Chem. Lab. Med. 49(3), 345-352 (2011).
14. Prvulovic D, Hampel H. Amyloid b (Ab) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease. Clin. Chem. Lab. Med. 49(3), 367-374 (2011).
15. Domenici E, Wille DR, Tozzi F, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS ONE 5(2), e9166 (2010).
16. Takahashi M, Hayashi H, Watanabe Y, et al. Diagnostic classification of schizophrenia by neural network analysis of blood-based gene expression signatures. Schizophr. Res. 119(1-3), 210-218 (2010).
17. Torres KC, Souza BR, Miranda DM, et al. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(2), 214-219 (2009).
18. Blier P, de Montigny C. Antidepressant monoamine oxidase inhibitors enhance serotonin but not norepinephrine neurotransmission. Psychopharmacol. Ser. 3, 127-134 (1987).
19. Ross RJ, Zavadil AP 3rd, Calil HM, et al. Effects of desmethylimipramine on plasma norepinephrine, pulse, and blood pressure. Clin. Pharmacol. Ther. 33(4), 429-437 (1983). (Pubitemid 13093761)
20. Veith RC, Lewis N, Linares OA, et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch. Gen. Psychiatry 51(5), 411-422 (1994). (Pubitemid 24176819)
21. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J. Clin. Pharmacol. 40(2), 161-167 (2000).
22. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JH, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 8(1), 23-33 (1993). (Pubitemid 23011155)
23. Vincent S, Bieck PR, Garland EM, et al. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 109(25), 3202-3207 (2004).
24. Leibowitz MEL, Lin Q, Ledent E, et al. Use of a biomarker of norepinephrine transporter (NET) inhibition to assess atomoxetine effects during clinically recommended dosing. Presented at: Proceedings of the 18th ECNP Congress. Amsterdam, The Netherlands, 22-26 October 2005.
25. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol. Psychiatry 53(2), 112-120 (2003). (Pubitemid 36126473)
26. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27(5), 699-711 (2002). (Pubitemid 35335888)
27. Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D. The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov. Today 14(9-10), 509-515 (2009).
28. Giannoni P, Medhurst AD, Passani MB, et al. Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5- tetrahydro-1H-3- benzazepin-7-yl)oxy]-N-methyl-3-p yridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J. Pharmacol. Exp. Ther. 332(1), 164-172 (2010).
29. Soares H, Wager T, Schmidt A, et al. H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers. Alzheimers Dement. 5(4), 254-255 (2009).
30. Sellin AK, Shad M, Tamminga C. Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr. 13(11), 985-996 (2008).
31. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258(5080), 304-307 (1992).
32. Fisher A, Michaelson DM, Brandeis R, Haring R, Chapman S, Pittel Z. M1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann. NY Acad. Sci. 920, 315-320 (2000). (Pubitemid 32056587)
33. Beach TG, Walker DG, Potter PE, Sue LI, Fisher A. Reduction of cerebrospinal fluid amyloid b after systemic administration of M1 muscarinic agonists. Brain Res. 905(1-2), 220-223 (2001). (Pubitemid 32553856)
34. Hock C, Maddalena A, Raschig A, et al. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A b 42 in patients with Alzheimer's disease. Amyloid 10(1), 1-6 (2003). (Pubitemid 36520922)
35. Maes M, Meltzer HY, Bosmans E, et al. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J. Affect. Disord. 34(4), 301-309 (1995).
36. Price LH, Rasmussen SA. Stress and depression: is neuroimmunology the missing link? Harv. Rev. Psychiat. 5(2), 108-112 (1997). (Pubitemid 27333282)
37. Connor TJ, Kelly JP, Leonard BE. Forced swim test-induced endocrine and immune changes in the rat: effect of subacute desipramine treatment. Pharmacol. Biochem. Behav. 59(1), 171-177 (1998). (Pubitemid 28053695)
38. Maier SF, Watkins LR. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res. 695(2), 279-282 (1995).
39. Asnis GM, De La Garza R 2nd. Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. J. Clin.Gastroenterol. 40(4), 322-335 (2006). (Pubitemid 44309525)
40. Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-a: characteristics and vulnerability. J. Psychosom. Res. 63(2), 131-135 (2007). (Pubitemid 47088561)
41. Malek-Ahmadi P. Cytokines and etiopathogenesis of pervasive developmental disorders. Med. Hypothes. 56(3), 321-324 (2001). (Pubitemid 32382350)
42. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40(4), 171-176 (1999). (Pubitemid 29515729)
43. Stubner S, Schon T, Padberg F, et al. Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neurosci. Lett. 259(3), 145-148 (1999). (Pubitemid 29059605)
44. Carpenter LL, Heninger GR, Malison RT, Tyrka AR, Price LH. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. J. Affect. Disord. 79(1-3), 285-289 (2004). (Pubitemid 38340558)
45. Lindqvist D, Janelidze S, Hagell P, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol. Psychiat. 66(3), 287-292 (2009).
46. Raison CL, Borisov AS, Majer M, et al. Activation of central nervous system inflammatory pathways by interferon-a: relationship to monoamines and depression. Biol. Psychiat. 65(4), 296-303 (2009).
47. Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatrica Scand. 97(4), 309-313 (1998). (Pubitemid 28179269)
48. Haack M, Hinze-Selch D, Fenzel T, et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J. Psychiatr. Res. 33(5), 407-418 (1999). (Pubitemid 29392689)
49. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22(4), 370-379 (2000). (Pubitemid 30105765)
50. Kubera M, Kenis G, Bosmans E, et al. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol. J. Pharmacol. 52(3), 237-241 (2000). (Pubitemid 30479574)
51. Kagaya A, Kugaya A, Takebayashi M, et al. Plasma concentrations of interleukin-1b, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor a of depressed patients in Japan. Neuropsychobiology 43(2), 59-62 (2001). (Pubitemid 32149726)
52. Hirohata S, Kanai Y, Mitsuo A, Tokano Y, Hashimoto H. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin. Rheumatol. 28(11), 1319-1323 (2009).
53. Fragoso-Loyo H, Richaud-Patin Y, Orozco-Narvaez A, et al. Interleukin-6 and chemokines in the neuropsychiatric manifestations of systemic lupus erythematosus. Arthritis Rheum. 56(4), 1242-1250 (2007). (Pubitemid 46608649)
54. Vila N, Chamorro A, Castillo J, Davalos A. Glutamate, interleukin-6, and early clinical worsening in patients with acute stroke. Stroke 32(5), 1234-1237 (2001).
55. Torre D, Zeroli C, Ferraro G, et al. Cerebrospinal fluid levels of IL-6 in patients with acute infections of the central nervous system. Scand. J. Infect. Dis. 24(6), 787-791 (1992). (Pubitemid 23047112)
56. Donato R, Sorci G, Riuzzi F, et al. S100B's double life: intracellular regulator and extracellular signal. Biochim. Biophys. Acta 1793(6), 1008-1022 (2009).
57. Rothermundt M, Falkai P, Ponath G, et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol. Psychiatry 9(10), 897-899 (2004). (Pubitemid 39381953)
58. Steiner J, Bielau H, Bernstein HG, Bogerts B, Wunderlich MT. Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones. J. Neurol. Neurosurg. Psychiatry 77(11), 1284-1287 (2006). (Pubitemid 44654765)
59. Schwarz E, Bahn S. Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Exp. Rev. Mol. Diagn. 8(2), 209-216 (2008). (Pubitemid 351469440)
60. Thompson PM, Rosenberger C, Qualls C. CSF SNAP-25 in schizophrenia and bipolar illness. A pilot study. Neuropsychopharmacology 21(6), 717-722 (1999).
61. Kozlovsky N, Regenold WT, Levine J, Rapoport A, Belmaker RH, Agam G. GSK-3b in cerebrospinal fluid of schizophrenia patients. J. Neural Transm. 111(8), 1093-1098 (2004). (Pubitemid 39037129)
62. Li S, Wu H, Guo H, Zhao Z. Neuron-specific enolase and myelin basic protein in cerebrospinal fluid of patients with first episode schizophrenia. J. Huazhong Univ. Sci. Technol. Med. Sci. 26(2), 228-230 (2006).
63. Fell MJ, Witkin JM, Falcone JF, et al. N-(4-((2-(trifluoromethyl)-3- hydroxy-4- (isobutyryl)phenoxy)methyl)benzyl)- 1-methyl-1H-imidazole-4- carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes. J. Pharmacol. Exp. Ther. 336(1), 165-177 (2011).
64. Lowe JA 3rd, Hou X, Schmidt C, et al. The discovery of a structurally novel class of inhibitors of the type 1 glycine transporter. Bioorg. Med. Chem. Lett. 19(11), 2974-2976 (2009).
65. Huang JT, Leweke FM, Oxley D, et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med. 3(11), e428 (2006).
66. Huang JT, Leweke FM, Tsang TM, et al. CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One 2(8), e756 (2007).
67. Craig-Schapiro R, Kuhn M, Xiong C, et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 6(4), e18850 (2011).
68. Trojanowski JQ, Vandeerstichele H, Korecka M, et al. Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement. 6(3), 230-238 (2010).
69. Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom. Rev. 26(1), 51-78 (2007). (Pubitemid 46051813)
70. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29(11), 1181-1189 (1999).
71. Holmes E, Tsang TM, Huang JT, et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med. 3(8), e327 (2006).
72. Ben-Shachar D, Laifenfeld D. Mitochondria, synaptic plasticity, and schizophrenia. Int. Rev. Neurobiol. 59, 273-296 (2004). (Pubitemid 39752419)
73. Kato T, Kato N. Mitochondrial dysfunction in bipolar disorder. Bipolar Disord. 2(3 Pt 1), 180-190 (2000).
74. Quiroz JA, Gray NA, Kato T, Manji HK. Mitochondrially mediated plasticity in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33(11), 2551-2565 (2008).
75. Rezin GT, Amboni G, Zugno AI, Quevedo J, Streck EL. Mitochondrial dysfunction and psychiatric disorders. Neurochem. Res. 34(6), 1021-1029 (2009).
76. Regenold WT, Phatak P, Marano CM, Sassan A, Conley RR, Kling MA. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol. Psychiatry 65(6), 489-494 (2009).
77. Simonsen AH, Bech S, Laursen I, et al. Proteomic investigations of the ventriculo-lumbar gradient in human CSF. J. Neurosci. Methods 191(2), 244-248 (2010).
78. Tarnaris A, Toma AK, Chapman MD, et al. Rostrocaudal dynamics of CSF biomarkers. Neurochem. Res. 36(3), 528-532 (2011).
79. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65(4), 403-413 (2009).